Paul Carter
Director/Board Member at HUTCHMED (CHINA) LIMITED
Net worth: 677 259 $ as of 2024-04-29
Paul Carter active positions
| Companies | Position | Start | End |
|---|---|---|---|
| HUTCHMED (CHINA) LIMITED | Director/Board Member | 2017-01-31 | - |
| Independent Dir/Board Member | 2017-01-31 | - | |
| IMMATICS N.V. | Director/Board Member | 2020-06-30 | - |
| Independent Dir/Board Member | 2020-06-30 | - | |
| AWAKN LIFE SCIENCES CORP. | Director/Board Member | 2021-12-13 | - |
| Independent Dir/Board Member | 2021-12-13 | - | |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Chairman | 2020-05-13 | - |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Director/Board Member | 2022-01-25 | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - | - |
Career history of Paul Carter
Former positions of Paul Carter
| Companies | Position | Start | End |
|---|---|---|---|
| VECTIVBIO HOLDING AG | Director/Board Member | 2021-09-01 | 2023-06-25 |
| Independent Dir/Board Member | 2021-09-01 | 2023-06-25 | |
| MALLINCKRODT PLC | Director/Board Member | 2018-05-15 | 2022-06-15 |
| Independent Dir/Board Member | 2018-05-15 | 2022-06-15 | |
| ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 2015-05-31 | 2019-10-31 |
| Independent Dir/Board Member | 2015-05-31 | 2019-10-31 | |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Paul Carter
| University of West London | Undergraduate Degree |
Statistics
International
| United States | 4 |
| United Kingdom | 4 |
| Switzerland | 3 |
Operational
| Director/Board Member | 8 |
| Independent Dir/Board Member | 6 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 10 |
| Consumer Services | 2 |
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 6 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| HUTCHMED (CHINA) LIMITED | Health Technology |
| MALLINCKRODT PLC | Health Technology |
| GSK PLC | Health Technology |
| IMMATICS N.V. | Health Technology |
| AWAKN LIFE SCIENCES CORP. | Health Services |
| Private companies | 5 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Technology Services |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Paul Carter
- Experience
